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Summary: Blood monocytes or intimal smooth muscle cells from normal aorta were incubated with low
density lipoprotein (LDL) from patients with coronary atherosclerosis, or with LDL from diabetic patients,
or with lipoprotein(a) (Lp(a)). In each case there was a 2- to 4-fold rise in the intracellular cholesteryl ester
content. LDL from healthy subjects failed to induce intracellular lipid accumulation in these cells. LDL from
patients with coronary atherosclerosis, LDL from diabetic patients, and Lp(a) form aggregates under cell
culture conditions. The ability of these lipoproteins to increase the cholesteryl ester content of cultured cells
is directly correlated to the degree of lipoprotein aggregation. When aggregates were removed from the
lipoprotein preparations by filtration, the latter became less effective in promoting intracellular lipid accu-
mulation. Incubation of cells with lipoprotein aggregates, isolated by gel filtration, induced a 3- to 5-fold
elevation of the cellular cholesteryl ester content.
These results suggest that LDL from artherosclerotic patients, or LDL from diabetic patients, or Lp(a) have
a tendency to form aggregates and that these aggregates are avidly taken up by intimal smooth muscle cells
followed by lipid accumulation. This aggregation tendency may play a role in atherogenesis.
Introduction . . . - « „ ucations in vitro form aggregates under cell culture
The accumulation of cholesteryl esters in intimal conditions (11). The degree of aggregation of modified
smooth muscle cells is one of the earliest manifesta- LDL is correlated with their ability to increase the
tionsof atherosclerosis. Despite intensive investigative intracellular cholesterol ester content. Removal of
work, the molecular mechanisms underlying lipid dep- these aggregates from preparations of modified LDL
osition within the cells still remain unknown. Native resulted in a marked suppression of lipid accumula-
LDL properly isolated from healthy subjects fails to tion in cultured cells. These findings demonstrate that
induce intracellular lipid accumulation in cultured the ability of in vitro modified LDL to promote in-
cells (1 — 3), while incubation of cells with LDL chem- tracellular lipid deposition depends largely on its ag-
ically modified by acetylation, methylation, glyc- gregation. Several types of modified LDL have been
ation, oxidation, desialylation, or by malondialde- shown to occur in human blood. Thus Curtiss &
hyde, glutaraldehyde or 4-hydroxynonenal treatment Witztum (12) demonstrated the presence of glyc-
results in deposition of lipid within the cells (1,3, ated LDL in the circulation of hyperglycaemic dia-
4 — 10). We recently reported that LDL after modifi- betic patients, and recently it was shown that LDL
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from atherosclerotic patients differs from LDL from
healthy donors by a lower content of sialic acid (8,
9). This desialylated lipoprotein species induces intra-
cellular lipid accumulation in cultured aortic cells (13,
14). Another circulating lipoprotein, which has been
implicated in the deposition of lipids into cells (15 —
18) is lipoprotein(a) (Lp(a)). This lipoprotein is similar
to LDL but in addition to apolipoprotein B-100, it
also contains the Lp(a) glycoprotein, apolipoprotein
(a). The molecular mass of apolipoprotein(a) ranges
from 350000 to 900000 depending on the genetic
isoform (19). In many epidemiological studies a po-
sitive correlation of high serum Lp(a) concentrations
with coronary heart disease has been demonstrated
(20-22).
The present work was undertaken to study whether
1) LDL isolated from subjects suffering from coro-
nary heart disease or diabetes show an increased tend-
ency to form aggregates under cell culture conditions,
2) whether LDL aggregates or Lp(a) aggregates cause
accumulation of cholesteryl esters into aortic intimal
cells in culture, and
3) whether removal of these aggregates results in a
decrease in intimal cholesteryl ester accumulation.
Materials and Methods
Preparation of l ipoproteins
Low density lipoprotein (d = 1.019 — 1.055 kg/1) was isolated
by sequential ultracentrifugation (23) from:
1) combined plasma from 12 healthy subjects,
2) from 12 patients with coronary heart disease (angiographi-
cally documented stenosis of coronary arteries), and
3) from 12 non-insulin-dependent diabetic patients.
The clinical characteristics of the coronary heart disease patients
and the healthy donors have been described (13, 14, 24). None
of the coronary heart disease patients or the healthy donors
had diabetes mellitus. In the three groups the mean cholesterol
concentrations were essentially similar, i.e. 5.12 + 0.33, 5.04
± 0.26 and 4.76 ±0.13 mmol/1 for coronary heart disease
patients, diabetic patients and healthy subjects, respectively.
HDL-cholesterol concentrations in respective groups were 0.96
± 0.10, 1.01 ± 0.08 and 1.14 ± 0.16 mmol/1. Plasma apoli-
poprotein B concentrations were 0.99 ± 0.07, 0.98 ± 0.09 and
0.88 ± 0.06 g/1, respectively for coronary heart disease and
diabetic patients and for healthy subjects.
To prevent lipoprotein oxidation and proteolysis, butylated
hydroxytoluene (final concentration 2 μηιοΙ/1) and phenylme-
thylsulphonyl fluoride (final concentration 1 mmol/1) were
added. After recentrifugation at d = 1.055 kg/1, the LDL prep-
arations were dialysed against phosphate-buffered saline, fil-
tered through a 0.22 μιη polycarbonate filter and stored for a
maximum of 7 days at + 4 °C. Immediately before use, the
preparations were refilteted. The main characteristics of the
LDL preparations obtained are summarized in table 1. The
sialic acid content was determined by the method of Warren
(25). The extent of LDL glycation was evaluated from the
fructosyl-lysine content, as determined by the method of Kruse-
Jarres et al. (26) using Boehringer Mannheim kits (Mannheim,
Germany). The level of thiobarbituric acid reactive products in
LDL and Lp(a) preparations was determined according to Yagi
(27).
Lipoprotein(a) was isolated by sequential ultracentrifugation,
gel filtration on Sepharose 4B, and chromatography on Heparin
Sepharose, as described previously (28, 29).
Determination of the degree of l ipoprotein aggre-
gation and the size of aggregates
The degree of lipoprotein aggregation was evaluated by meth-
ods based on analysis of light transmission fluctuations in LDL
and Lp(a) suspensions (30). The aggregate size was determined
by quasi-elastic laser scattering on an Autosizer 2 (Malvern
Instrument, U. K.).
Cell cul ture
Subendothelial cells were isolated from grossly normal intima
by dispersion of human aortic tissue with 1.5 g/1 collagenase,
and cultured in growth medium containing Medium 199, fetal
calf serum, volume fraction 0.1, 2 mmol/1 L-glutamine, and
antibiotics (GIBCO Europe, Paisley) as described previously
(31). The cells were cultured at 37 °C in a humidified CO2-
incubator (0.95 air/0.05 CO2). The medium was changed every
day. Starting from the 7th day in primary culture, cells were
incubated for 6 h in medium containing LDL from healthy
donors, or LDL from coronary heart disease patients or dia-
betic patients (protein 100 mg/1) and lipoprotein-deficient
serum, volume fraction 0.1 (prepared by ultracentrifugation
(23) from a healthy donor (d > 1.250 kg/1)). Medium and
lipoprotein preparations were filtered (0.22 μιη pore size) im-
mediately before adding to cell cultures. Human peripheral
blood monocytes were isolated and incubated with lipoprotein
preparations as described previously (24). After incubation the
cells were rinsed and cellular lipids determined, as described
below.
Analytical methods
Protein was determined by the method of Lowry et al. (32).
Intracellular lipids were extracted with a w-hexane-isopropanol
mixture (3 + 2, by vol.) as described elsewhere (33). To determine
the cholesterol ester content, the amount of free and total
cholesterol was measured by the method of Siedel (34) using
Boehringer Mannheim reagents (Mannheim, Germany). Lipids
were extracted from lipoproteins with a chloroform-methanol
mixture (2+1, by vol.) according to Bligh & Dyer (35). Phos-
pholipids and neutral lipids were separated by thin-layer chro-
matography and measured by scanning densitometry (31). Li-
poprotein(a) was quantitated with an immunoradiometric
(IRMA)-method as described previously (36).
Statistical analysis
The significance of differences between groups was evaluated
by multiple t-test of one-way analysis of variance using a BMDP
statistical program package (37). The Bonferoni method was
used to compare the study groups with the control group (38).
Results
Characterization of lipoprotein preparations
Table 1 shows some characteristics of the lipoprotein
preparations examined in the present study. The pro-
tein and lipid composition of LDL obtained from
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healthy subjects and atherosclerotic or diabetic pa-
tients are essentially similar. There was no significant
difference in the content of thiobarbituric acid reactive
substance between LDL preparations obtained from
healthy subjects and patients. The sialic acid content
in LDL of coronary heart disease patients was 3-fold
lower than that measured in LDL of healthy subjects.
In LDL of diabetic patients a high content of fruc-
tosyl-lysine was present due to enhanced glycation
(tab. 1).
In Lp(a) isolated from coronary heart disease subjects
the ratios between the major lipid classes were similar
to those in LDL from healthy donors. The sialic acid
content of Lp(a) was approximately 13-fold higher
than that of LDL, while the thiobarbituric acid re-
active substance content did not differ significantly
from that of LDL.
Effect of lipoproteins on intracellular lipid
accumulation
When intimal cells (cultured from grossly normal
human aorta) were incubated in the presence of the
different lipoprotein preparations, they accumulated
varying quantities of cholesteryl esters (tab. 2).
After 6 h of incubation, LDL from healthy donors
induced no significant increase in the intracellular
cholesterol ester content. In contrast, LDL isolated
from coronary heart disease patients significantly in-
creased the cholesteryl ester content of the cultured
cells (tab. 2). The intracellular cholesteryl ester con-
tent also increased after the cells had been incubated
with LDL preparations from diabetic patients. This
6-h incubation of intimal cells with patient-LDL or
LDL of healthy donors produced no significant in-
crease in the intracellular content of free cholesterol
(data not shown).
Tab. 2. Effect of LDL from healthy donors, coronary heart
disease patients and diabetic patients on cholesteryl
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Aortic intimal cells or monocytes were incubated for 6 h in
Medium 199 containing lipopro tern-deficient serum, volume
fraction 0.1 and freshly filtered (0.22 μιη pore diameter) lipo-
protein preparations (protein concentration 100 and 50 mg/1,
respectively). Control cells were incubated in Medium 199 con-
taining lipoprotein deficient serum, volume fraction 0.1. The
data are the mean of 4 determinations ± SEM.
* significant difference from the control, p < 0.05.
Lipoprotein(a), at a concentration of 100 mg/1, in-
duced a 3-fold increase in esterified cholesterol, but
not in the free cholesterol content of the cells (tab.
2), compared with the concentration observed after
incubation of the cells with LDL from healthy donors.
We also examined the effects of LDL and Lp(a) on
the cholesteryl ester content of human peripheral
blood monocytes. At a concentration of 50 mg/1, LDL
isolated from coronary heart disease patients or dia-
betic patients, as well as Lp(a) promoted a 2 to 3-
fold rise in intracellular cholesteryl ester in cultured
monocytes (tab. 2), compared with that observed after
incubation with LDL from healthy donors.
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Lipoprotein aggregation under cell culture
conditions
Table 3 illustrates alterations in average particle size
for lipoprotein preparations incubated with cultured
cells at 37 °C in medium 199 containing lipoprotein-
deficient serum, volume fraction 0.05. LDL isolated
from healthy donors demonstrated no appreciable
change in average particle size for up to 24 h of
incubation. In contrast, when LDL from atheroscler-
otic patients, or LDL from diabetic patients, or Lp(a)
were incubated in the presence of cells, a significant
increase in the average particle size of LDL and Lp(a)
was observed within 6 hours of incubation (tab. 3).
Tab. 3. Alterations in the average size of lipoprotein particles
during incubation under the conditions of cell culture.
Average particle size
(rel. units)
Time of incubation (h)
0 6 24
LDL of healthy subjects 5.4 5.6 5.9
Coronary heart disease patients' LDL 5.8 12.9 23.4
Diabetic patients'LDL 6.1 15.7 27.8
Lipoprotein (a) 7.8 10.4 20.7
Freshly filtered (0.22 μηι) preparations of LDL of healthy
subjects, coronary heart disease and diabetic patients, or lipo-
protein (a) were incubated in Medium 199 containing lipopro-
tein-deficient serum, volume fraction 0.05 with smooth muscle
cells from grossly normal human aortic intima for the indicated
time period. Lipoprotein average size was determined by laser
correlative photometry.
A direct and strong correlation (r = 0.88, η = 28,
ρ < 0.01) was established between the degree of li-
poprotein aggregation and cholesteryl ester accumu-
lation in cultured intimal cells. The diameters of gly-
cated, desialylated LDL and lipoprotein(a) aggregates
were 70-200, 100-500 and 200-400 nm, respec-
tively, as determined by laser spectroscopy. The av-
erage diameters of LDL and lipoprotein(a) particles
from healthy subjects were 27 nm and 35 nm, respec-
tively.
Effect of aggregate removal from lipoprotein
preparations
To study the role of lipoprotein aggregates on lipid
accumulation in cultured cells, we removed aggre-
gated lipoproteins from LDL preparations by filtra-
tion. For this purpose filtered LDL preparations that
had been incubated for 6 h at 37 °C with cells were
again passed through polycarbonate filters to remove
aggregates. The filtered LDL was then incubated with
cultured intimal cells under the same conditions as
previously. Subsequently, LDL aggregation and in-
tracellular cholesteryl ester content were analysed.
After filtration, the average diameters of aggregates
in filtered preparations of LDL from coronary heart
disease patients were significantly reduced, compared
with those in the initial preparations (tab. 4). When
cells were incubated with these refiltered preparations,
a much lower cholesteryl ester accumulation was ob-
served, and when the LDL-preparations were passed
through 0.1 μηι filters they completely lost their ability
to induce intracellular lipid accumulation.
Lipoprotein aggregates were also removed by gel fil-
tration. After passage through a Sepharose CL-2B
column, isolated preparations of Lp(a), or patient-
LDL, which initially caused intracellular lipid depo-
sition in intimal cells, lost their ability to increase lipid
accumulation (tab. 5).
As shown in table 5, aggregates of LDL from ather-
osclerotic or diabetic patients, as well as Lp(a) aggre-
Tab. 4. Effect of lipoprotein filtration on their ability to induce the accumulation of cholesteryl esters in the smooth muscle cells
of unaffected human aortic intima and human blood monocytes.
LDL of healthy subjects




























LDL preparations were filtered through 0.22 μηι filters and preincubated for 6 h in Medium 199 containing lipoprotein-deficient
serum, volume fraction 0.05. After preincubation, LDL preparations were carefully filtered through 0.1 μηι, 0.22 μηι and 0.45 μηι
filters and added to cells at an apolipoprotein Β concentration of 0.1 g/1. Following 6 h of incubation, cells were rinset and their
cholesteryl ester content was measured. Values listed are means of 4 determinations + SEM.
* significant difference from the control, p < 0.01.
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Tab. 5. Effects of aggregated and non-aggregated LDL on the




Tab. 6. Effect of aggregated.lipoprotein on the cholesteryl ester





healthy subjects 7 ± 12 4 + 7
Coronary heart
disease patients'
LDL 103 ± 7 * 17 ± 11
Diabetic patients'
LDL 187 ±20* 5 ± 8





Freshly filtered lipoprotein preparations were preincubated for
6 h at 37 °C. Aggregated and non-aggregated modified lipopro-
tein were separated by gel filtration on a Sepharose CL-2B
column (1.6 χ 90 cm) at a flow rate of 1.5 ml/min. Fractions
of aggregated and non-aggregated lipoproteins were pooled and
examined for their ability to induce cholesteryl ester accumu-
lation in cultured smooth muscle cells from grossly normal
human aortic intima. The data are the means of 4 determina-
tions ± SEM.
* significant difference from control, p < 0.05. Control cells
were incubated in Medium 199 with lipoprotern-deficient
serum, volume fraction 0.1. Cholesteryl ester concentration
in control smooth muscle cells was 29 ± 3 mg/g protein.
gates, induced a 4 —5-fold increase in intracellular
cholesterol ester content. Similar results were obtained
for cultured human peripheral blood monocytes (tab.
6). To find out whether the uptake of LDL aggregates
was mediated by phagocytosis, we examined the in-
fluence of the phagocytosis inhibitor, cytochalasin B,
on the cholesteryl ester accumulation in cultured cells
caused by aggregates. This agent inhibited the increase
of cholesteryl ester level both in smooth muscle cells
and in monocytes (tab. 7).










Human peripheral blood monocytes were incubated for 6 h in
Medium 199 containing lipoprotein deficient serum, volume
fraction 0.1 and 50 mg/1 of aggregated lipoproteins. Aggregated
lipoproteins were obtained as indicated in the legend to table
5. Control cells were incubated in the absence of lipoprotein
aggregates. The data are the means of 4 determinations
±SEM.
* significant difference from control, p < 0.05. Control cells
were incubated in Medium 199 with lipoprotein deficient
serum, volume fraction 0.1. The amount of cholesteryl ester
in control monocytes was 6 + 1 mg/g protein.
Discussion
The present study demonstrates the LDL isolated
from patients with coronary heart disease or diabetes,
as well as lipoprotein(a), induce accumulation of cho-
lesteryl esters in cultured human aortic intimal cells
and in peripheral blood monocytes. This is in contrast
to LDL isolated from healthy subjects using the same
techniques. We have previously shown that in vitro
modified LDL undergoes aggregation, and that this
aggregation of the modified LDL plays a crucial role
in intracellular lipid accumulation (11).
It was therefore of interest to study whether LDL
isolated from patients might in vivo have been modi-
fied in such a way that they display a tendency to
aggregate.
Here we provide evidence that LDL isolated from
patients with coronary heart disease or diabetes mel-
Tab. 7. Effects of cytochalasin B on cholesteryl ester accumulation in intimal smooth muscle cells and human monocytes.
Cholesteryl ester content, mg/g protein
Intimal smooth muscle cells
Cytochalasin B, 10 mg/1
Monocytes
Details of the experiments are the same as described in tables 5 and 6.
* significant difference from samples without cytochalasin B, p < 0.05.
Control
Aggregates of LDL from coronary heart disease patients
Aggregates of LDL from diabetic patients












7 ± 1 *
8 + 1*
8 + 1*
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litus show an increased tendency to form aggregates.
In contrast, LDL from healthy donors do not aggre-
gate to a measurable degree under the experimental
conditions used in this study. Thus, some kind of
lipoprotein modification appears to take place in vivo
under pathological conditions such as atherosclerosis
and diabetes. The mechanisms underlying the in-
creased tendency for lipoprotein aggregation is at
present unclear. The changes in the lipid or protein
moieties leading to increased aggregation may include
a wide range of chemical modifications.
Fogelman et al. (5) were the first to demonstrate that
LDL cross-linked by glutaraldehyde induced choles-
teryl ester accumulation in human monocyte-macro-
phages. Recently, Hoffet al. reported that 4-hydroxy-
nonenal, produced upon lipid peroxidation, is capable
of causing cross-linking of lipoproteins (39) and that
the lipoprotein aggregates thus formed elevate the
intracellular cholesteryl ester concentration in cul-
tured macrophages. Khoo et al. reported that aggre-
gates prepared by vortexing LDL suspension promote
lipid accumulation in macrophages, but not in smooth
muscle cells (40). Our earlier findings show (11) that
in vitro modified LDL spontaneously aggregate under
the conditions of cell culture and that his aggregation
is a necessary step in the process of cholesteryl ester
accumulation within cultured human aortic smooth
muscle cells. The present study indicates that, under
these conditions, in vivo modified LDL also undergoes
aggregation, and is able to increase the cholesteryl
ester content of cultured aortic smooth muscle cells.
In addition, cytochalasin B, an inhibitor of cellular
phagocytosis, decreased the uptake and degradation
of LDL aggregates. These findings strongly suggest
that phagocytosis is the mechanism responsible for
the uptake of LDL aggregates.
In earlier work it was demonstrated that oxidized and
malondialdehyde-treated LDL show an increased
tendency for aggregation (11). Jürgens demonstrated
that lysophosphatidylcholine can provoke aggrega-
tion of Lp(a) (41). On the other hand, we have found
that modified LDL and Lp(a) bind to native LDL
(Tertov et al., unpublished data), an observation con-
sistent with the findings of Ye et al. (42). These data
suggest that the aggregates may consist of both mod-
ified and native LDL.
In addition to LDL aggregates, "associates" between
lipoproteins and various connective tissue compo-
nents, such as proteoglycans (43, 44), collagenase-
resistent debris (45), heparin-fibronectin-denaturated
collagen (46), fibronectin (47), and elastin (48) have
been described. All these "associates" seem to be able
to induce lipid accumulation in macrophages and
smooth muscle cells. Recently, an association of LDL
with mast cells and subsequent proteolytic modifica-
tion of LDL were described, and it was shown that
these mast cell-modified LDL are able to increase the
cholesterol ester content of macrophages (49 — 51).
LDL-antibody complexes elicit the same effect (52).
Taken together, these data suggest that the formation
of lipoprotein-aggregates favour the accumulation of
cholesterol esters in human aortic intimal cells, and
may play an important role in atherogenesis.
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